Citius Oncology shares surge 15.86% intraday as LYMPHIR gains strong institutional adoption and payer coverage post-launch.

Citius Oncology surged 15.86% intraday following the announcement of a strong commercial update on its LYMPHIR™ launch. The company highlighted early adoption by leading cancer centers, 83% formulary review progress among target accounts, and broad payer coverage across ~135 health plans, representing ~80% of covered lives. The absence of reimbursement barriers and initial expansion into community infusion centers signaled robust market access and clinical integration. Positive topline data from investigator-led studies, including combinations with pembrolizumab and pre-CAR-T use in lymphoma, further reinforced LYMPHIR™’s potential in broader oncology applications. These developments collectively drove significant investor optimism, reflecting strong commercial and clinical momentum for the product.